CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 154 enrolled
Drug / intervention
Atenolol (β-blocker)drug
Likely dose
Atenolol (β-blocker) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00837902
NCT00837902N/ACompleted
CompareCT.gov

Genetic Determinants of Response to Beta Blockade

Vanderbilt University·interventional·Posted Feb 6, 2009·Updated Nov 30, 2018

In Brief

A clinical study evaluating Atenolol (β-blocker) for Healthy. Completed, enrolled 154 participants across 1 site.

Detailed Summary

The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), National Center for Research Resources (NCRR)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 6, 2009
Enrollment StartJan 1, 2009
Primary CompletionDec 31, 2012
Study CompletionDec 31, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.4 years ago

Interventions

Atenolol (β-blocker)drug

25 mg tablet